

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q4 17-18	Q4 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Formulations Business - Key Markets	27,196	20,299	34.0%	99,290	77,024	28.9%
US Formulations	16,424	9,851	66.7%	58,348	37,090	57.3%
India Formulations	8,838	8,402	5.2%	33,324	32,441	2.7%
Latin America Formulations	663	603	9.9%	2,605	2,445	6.5%
Emerging Markets Formulations	1,271	1,444	-12.0%	5,014	5,048	-0.7%
Other Businesses and Alliances	4,331	4,227	2.5%	17,018	16,608	2.5%
Europe Formulations	602	620	-2.9%	2,404	2,623	-8.4%
Consumer Wellness	1,284	1,200	7.0%	4,920	4,593	7.1%
Animal Health & Others	1,128	959	17.7%	4,445	4,005	11.0%
APIs	900	934	-3.6%	3,656	3,795	-3.7%
Alliances	415	514	-19.2%	1,593	1,591	0.1%
Grand Total	31,527	24,526	28.5%	116,307	93,632	24.2%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q4 17-18	Q4 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Other Operating Income	975	606	60.8%	3,056	2,092	46.1%
Export Incentive	347	214	62.3%	1,371	859	59.5%
Royalty Income	0	2	-100.0%	8	68	-87.9%
Net Gain on foreign currency transactions and translation (Refer Note below)	181	-82	321.7%	181	112	62.6%
Others	446	473	-5.5%	1,496	1,053	42.0%

Note : There was a net gain of Rs. 223 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and a net gain of Rs. 29 Mio. included in other operating expenses in Q4 17-18. Thus, on aggregate level, there was a gain of Rs. 433 Mio. on operating transactions (above EBIDTA line) in Q4 17-18 vs loss of Rs. 346 Mio. in Q4 16-17. See details below for more clarity.

Rs. Mio.	Q4 17-18	Q4 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Other Income	288	731	-60.6%	1,132	1,284	-11.8%
Interest & Dividend income	172	162	5.9%	500	578	-13.4%
Profit on sale of investments	10	-11	189.3%	82	61	33.2%
Others	107	579	-81.6%	550	644	-14.6%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q4 17-18	Q4 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
A. On operating transactions (above EBIDTA line)	-433	346	-225.3%	-342	-62	-456.7%
a. Included in other operating income	-181	82	-321.7%	-181	-112	-62.6%
b. Included in cost of goods	-223	264	-184.5%	-161	50	-422.0%
c. Included in other expenses	-29					
B. On other income (pertaining to foreign currency borrowings)	153					
C. On Foreign Currency Borrowings (part of interest cost)	-159	-159	0.0%	-197	-185	-6.5%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-439	187	-335.2%	-539	-247	-118.8%

Details of R&D Expenses

Rs. Mio.	Q4 17-18	Q4 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Total R&D Expenses	1,768	2,180	-18.9%	8,634	7,539	14.5%

Consolidated Capex for Apr 17 - Mar 18

**Rs. 9824
Mio.**

R&D capex included in above for Apr 17 - Mar 18

**Rs. 456
Mio.**